Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior

Peptide receptor radionuclide therapy for metastatic paragangliomas

(2016) David J. Pinato et al.   MEDICAL ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy

(2016) David J. Pinato et al.   OncoImmunology

Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia

(2015) Muhammad Zaeem Noman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis

(2014) N.D. Niemeijer et al.   CLINICAL ENDOCRINOLOGY

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy

(2014) Simone Muenst et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas

(2014) Clarissa A Cassol et al.   MODERN PATHOLOGY

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

(2013) D J Pinato et al.   BRITISH JOURNAL OF CANCER

One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

(2013) Ségolène Hescot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction

(2013) I. Jochmanova et al.   JNCI-Journal of the National Cancer Institute

Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma

(2013) Akiyo Tanabe et al.   Hormones & Cancer

Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations

(2012) D J Pinato et al.   BRITISH JOURNAL OF CANCER

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas

(2011) Montserrat Ayala-Ramirez et al.   CANCER

Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

(2011) Oliver Gimm et al.   LANGENBECKS ARCHIVES OF SURGERY

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

(2009) Sara Gonias et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY